BACKGROUND: In advanced @entity356 (AGC), most clinical trials are designed on the basis of protein expression or gene amplification of specific genes. Recently, next-generation sequencing (NGS) allowed us to comprehensively profile the @entity5 gene status. This study aimed to elucidate the profiling between gene alterations and protein expression in AGC to aid in future clinical trials on AGC. @entity1 AND METHODS: Formalin-fixed, @entity982 -embedded @entity5 samples from 121 stage III/IV @entity356 @entity1 were examined for protein expression of @entity4149 kinase receptors (RTKs; @entity1722 , @entity470 , @entity1916 , and @entity7991 ) using immunohistochemistry (IHC). Furthermore, 409 @entity5 -related genes were sequenced to detect mutations and copy number variations using NGS. RESULTS: Most @entity1722 overexpression (IHC 3+) cases (80.0%) had @entity1722 amplification and did not have other RTK amplification or oncogene mutations. However, one-fourth of MET overexpression cases (25.0%) had @entity1722 alterations. @entity470 and @entity7991 overexpression cases had @entity1722 alterations or other gene alterations such as @entity984 or @entity10160 . On the other hand, most of the four RTK amplification cases (88.2%) were mutually exclusive with each amplification. However, RTK amplification did not simply correlate with protein overexpression, whereas cases with RTK high-level amplification had protein overexpression and rarely showed other co-existing gene alterations. CONCLUSION: AGC involves a complicated arrangement of protein expression and gene alterations. Comprehensive analyses of NGS and IHC will be necessary to design the optimal therapy for treating the appropriate population of @entity1 in future clinical trials.

Comprehensive analyses using next-generation sequencing and immunohistochemistry enable precise treatment in advanced XXXX .

@entity1 :: ('9606', 'Species') :: ['patients', 'PATIENTS'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'cancer'] @entity470 :: ('1956', 'Gene') :: ['EGFR'] @entity984 :: ('3845', 'Gene') :: ['KRAS'] @entity982 :: ('MESH:D010232', 'Chemical') :: ['paraffin'] @entity7991 :: ('2263', 'Gene') :: ['FGFR2'] @entity1916 :: ('4233', 'Gene') :: ['c-MET'] @entity4149 :: ('D014443', 'Chemical') :: ['tyrosine'] @entity10160 :: ('5290', 'Gene') :: ['PIK3CA'] @entity356 :: ('MESH:D013274', 'Disease') :: ['gastric cancer'] @entity1722 :: ('2064', 'Gene') :: ['ERBB2']
@entity356 :: (MESH:D013274,Disease) :: ['gastric cancer']
